Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

by leveraging and expanding its technology platforms to improve and enable molecules.

For more information on Nektar Therapeutics, please visit http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the progress and potential of the company's pipeline of proprietary drug candidates, the value and potential of the company's technology platform, and the company's position to enter into new strategic collaborations with third parties. These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage of development prior to regulatory approval for numerous reasons including, without limitation, safety and efficacy findings; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; (iv) the outcome of any future intellectual property or other litigation related to the company's proprietary product candidates or complex commercial agreements; (v) if the company is unable to establish and maintain collaboration partnerships on attractive commercial terms, our b
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Repligen Corporation (Nasdaq: RGEN ) today announced ... funding to support the ongoing development of new ... Association (MDA). This grant will support the ... manufacture of a drug candidate for human clinical ... provides important funding for Repligen,s research but it ...
(Date:12/15/2009)... Medical, Inc. (OTC Bulletin Board : AEMD) announced ... Comper have joined the Science Advisory ... Schorey and Dr. Comper are leading researchers in ... of Aethlon Medical, was recently formed to leverage ... being advanced as an adjunct therapy for Hepatitis-C ...
(Date:12/15/2009)... Company (NYSE: MOS ) plans to issue ... financial tables on Tuesday, January 5, 2010, after the ... Results will be available on Mosaic,s website at ... conference call with presentation slides on Wednesday, January 6, ... begin at 11:00 a.m. Eastern Standard Time (10:00 a.m. ...
(Date:12/15/2009)... BRIARCLIFF MANOR, N.Y., Dec. 15 On ... the International Society for Medical Publication Professionals (ISMPP) ... Physicians in London, UK. More than 100 attendees ... new forum for publication professionals, editors, publishers, medical ... world of medical publications and the impact of ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2
... (Nasdaq: NVAX ) today announced that it will ... release to be issued after 8:00 a.m. Eastern Time on ... call to discuss its financial results at 10:00 a.m. Eastern ... by Novavax President and Chief Executive Officer Dr. Rahul Singhvi ...
... Company Patents in Each of the Three Critical Areas ... Intradigm Corporation, a leading developer of targeted, systemic RNA ... Patent and Trademark Office (USPTO) has issued the company ... aspects of a potent small interfering RNA (siRNA) sequence. ...
... March 17 Hikma Pharmaceuticals today,announced strong revenue growth ... US Generics business. The weakness in the US was ... Injectable and Branded,businesses. CEO, Said Darwazah, said "The US ... in 2008 we had a loss there so in ...
Other Biology Technology:Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 2Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 3Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence 2
(Date:12/15/2009)... 2009 Economics, environmental impacts, social dynamics, and ... the overall success of an agroecosystem. Positive or ... forcing individuals and social groups to continuously adapt ... , Experiential learning theory suggests that knowledge ... experiences. Such lessons are especially valuable for environmental ...
(Date:12/15/2009)... American researchers found the fossil remains of a whale, 4.5 ... for the first time, the results of the decay and ... cetacean, possibly a baleen whale from the Mysticeti group. , ... remains of a whale from the Lower Pliocene (five million ... is the first time that the results of the processes ...
(Date:12/15/2009)... Group, a leading real-time and embedded technology engineering services ... three high school teams for the 2010 season of ... ). ,, The PTR Group will provide funding to ... The teams from Atholton HS in Columbia, MD, Rockwall ... Vienna, VA all have direct mentorship from engineers in ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2Louisiana 26apos 3Bs TCA Cellular Therapy 26apos 3Bs Findings Reported at World Stem Cell Summit Patients 26apos 3B Legs Saved from Amputation Usin 58110 1Louisiana 26apos 3Bs TCA Cellular Therapy 26apos 3Bs Findings Reported at World Stem Cell Summit Patients 26apos 3B Legs Saved from Amputation Usin 58110 2Louisiana 26apos 3Bs TCA Cellular Therapy 26apos 3Bs Findings Reported at World Stem Cell Summit Patients 26apos 3B Legs Saved from Amputation Usin 58110 3Kayentis the Leading Provider of the Unique 26quot 3BPaper Based e Trial 26quot 3B Solution has been Retained for Six New Clinical Studies in the U 58106 1Kayentis the Leading Provider of the Unique 26quot 3BPaper Based e Trial 26quot 3B Solution has been Retained for Six New Clinical Studies in the U 58106 2New stove dramatically improves lung health in Mexican women 58102 1New stove dramatically improves lung health in Mexican women 58102 2New stove dramatically improves lung health in Mexican women 58102 3
... Hopkins have discovered what they believe is the "smoking gun" ... of blood oxygen loss followed by a sudden restoration of ... Hopkins team found that the sudden oxygen bath triggered by ... toxic it kills the cells. The work was published in ...
... in a white lab coat hunched over a microscope ... the scientists who will meet at The American Physiological ... October 8-11 in Virginia Beach, Virginia. , ... animals that hibernate for months without suffering significant muscle ...
... sense of 165-million-year-old dino tracks may be to hang out ... the Red Gulch Dinosaur Tracksite in northern Wyoming. Because they ... have similar feet, emus turn out to be the best ... a long-lost coastline in the Middle Jurassic. , "We don't ...
Other Biology News:Cell death following blood 'reflow' injury tracked to natural toxin 2What animals can tell us about hemorrhage, organ transplants and aging 2What animals can tell us about hemorrhage, organ transplants and aging 3What animals can tell us about hemorrhage, organ transplants and aging 4Trotting with emus to walk with dinosaurs 2Trotting with emus to walk with dinosaurs 3
... for the rapid purification of linear 100 bp ... DNA band is excised from an,agarose gel and ... base of the column are a series of ... back while allowing DNA to selectively pass through ...
...
... For use in hybridization incubators ... and GL 45 size PP plug-seal ... seal. Available in three lengths to ... plug-seal caps and O-rings available separately. ...
... provides a simple and efficient method for purification ... PCR mixes. DNA fragments selectively absorbed in the ... extraction or at room temperature for PCR product ... 25 g of DNA can be purified with ...
Biology Products: